GCG and type 2 diabetes mellitus: In CD patients, high glucagon levels, glycated hemoglobin (HbA1c) levels higher than 34.5 mmol/mol (> 5.3%), and a glucose peak after pasireotide administration higher than 9 mmol/L (> 162 mg/dL) were associated with a higher risk of T2DM during pasireotide treatment.